KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Common Equity (2016 - 2025)

Historic Common Equity for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $8.7 billion.

  • Amgen's Common Equity rose 4732.01% to $8.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 billion, marking a year-over-year increase of 4732.01%. This contributed to the annual value of $8.7 billion for FY2025, which is 4732.01% up from last year.
  • Per Amgen's latest filing, its Common Equity stood at $8.7 billion for Q4 2025, which was up 4732.01% from $9.6 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's Common Equity ranged from a high of $9.6 billion in Q3 2025 and a low of $916.0 million during Q1 2022
  • Moreover, its 5-year median value for Common Equity was $6.5 billion (2021), whereas its average is $6.3 billion.
  • As far as peak fluctuations go, Amgen's Common Equity crashed by 9018.64% in 2022, and later soared by 48384.28% in 2023.
  • Quarter analysis of 5 years shows Amgen's Common Equity stood at $6.7 billion in 2021, then plummeted by 45.36% to $3.7 billion in 2022, then skyrocketed by 70.23% to $6.2 billion in 2023, then decreased by 5.7% to $5.9 billion in 2024, then surged by 47.32% to $8.7 billion in 2025.
  • Its Common Equity stands at $8.7 billion for Q4 2025, versus $9.6 billion for Q3 2025 and $7.4 billion for Q2 2025.